152 related articles for article (PubMed ID: 38351680)
1. Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.
Lee J; Lee DH; Park JE; Lee YH; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Korean J Intern Med; 2024 Mar; 39(2):318-326. PubMed ID: 38351680
[TBL] [Abstract][Full Text] [Related]
2. Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of malignant pleural effusion.
Wang K; Hu X; Chen Y; Yi X; Han X; Zhu D; Zhu B; Luo H
Clin Respir J; 2024 Jan; 18(1):e13705. PubMed ID: 37775991
[TBL] [Abstract][Full Text] [Related]
3. Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma: a predictive marker for EGFR mutation.
Lv YL; Liu HB; Yuan DM; Zhou L; Jin SX; Song Y
Transl Cancer Res; 2019 Aug; 8(4):1027-1034. PubMed ID: 35116846
[TBL] [Abstract][Full Text] [Related]
4. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
[TBL] [Abstract][Full Text] [Related]
5. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of
Kashiwabara K; Fuji S; Tsumura S; Sakamoto K
Anticancer Res; 2020 Feb; 40(2):1117-1121. PubMed ID: 32014962
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of pleural fluid to serum carcinoembryonic antigen ratio and delta value for malignant pleural effusion: findings from two cohorts.
Jiang MP; Wen JX; Hai L; Jiang TW; Huang JH; Chen H; Wang YF; Zheng WQ; Hu ZD; Yan L
Ther Adv Respir Dis; 2023; 17():17534666231155745. PubMed ID: 36927281
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
[TBL] [Abstract][Full Text] [Related]
10. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
[TBL] [Abstract][Full Text] [Related]
11. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
Song Z; Wang W; Li M; Liu J; Zhang Y
Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
14. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
15. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the diagnosis value of carcinoembryonic antigen in malignant pleural effusion].
Yu YX; Tong ZH; Zhou XX; Liang LR; Wang Z; Xu LL; Wang XJ; Wu YB; Li HJ; Lu Z
Zhonghua Yi Xue Za Zhi; 2018 Feb; 98(6):432-435. PubMed ID: 29429254
[No Abstract] [Full Text] [Related]
18. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
[TBL] [Abstract][Full Text] [Related]
19. Surgical intervention for non-small-cell lung cancer with minimal malignant pleural effusion.
Iwasaki M; Shimomura M; Ishihara S; Yamaguchi T; Kishimoto M; Ii T; Inoue M
Surg Today; 2023 Jun; 53(6):655-662. PubMed ID: 36310332
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
